Korro Bio, Inc.

Equities

KRRO

US5009461089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
62.93 ^USD	+7.52%		-5.71%	+31.30%

Apr. 24	Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	MT
Apr. 24	Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	MT

Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 26, 2024 at 04:03 pm EDT

Korro Bio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 81.17 million compared to USD 58.03 million a year ago. Basic loss per share from continuing operations was USD 53.08 compared to USD 227.42 a year ago.

Latest news about Korro Bio, Inc.

Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.	Apr. 21	CI
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P.	Apr. 16	CI
HC Wainwright Adjusts Korro Bio's Price Target to $115 From $100, Buy Rating Kept	Mar. 28	MT
RBC Boosts Price Target on Korro Bio to $90 From $70 on 'Increased Conviction for A1AT,' Keeps Outperform, Speculative Risk	Mar. 27	MT
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
BMO Capital Initiates Korro Bio With Outperform Rating, Price Target is $120	Feb. 27	MT
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency	Dec. 07	CI
HC Wainwright Starts Korro Bio With Buy Rating, $100 Price Target	Dec. 04	MT
RBC Initiates Korro Bio at Outperform, Speculative Risk With $70 Price Target, Says Lead Program 'May Be Best-in-Class' for A1AT Protein	Nov. 29	MT
Korro Bio, Inc. Appoints Rachel Meyers as Board of Directors, Member of Nominating and Corporate Governance Committee	Nov. 28	CI
Piper Sandler Starts Coverage on Korro Bio with Overweight Rating, $180 Price Target	Nov. 10	MT
Frequency Therapeutics, Inc.(NasdaqCM:FREQ) dropped from NASDAQ Composite Index	Nov. 03	CI
Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. from a group of shareholders.	Nov. 02	CI
Frequency Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
North American Morning Briefing : Stock Futures -2-	23-09-27	DJ
Baird Downgrades Frequency Therapeutics to Neutral From Outperform	23-09-26	MT

Chart Korro Bio, Inc.

Duration

Period

More charts

Company Profile

Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cellâs natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify oneâs genome. The Company's focus areas include the liver and central nervous system (CNS).

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Citizens JMP Life Sciences Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

62.93 USD

Average target price

130 USD

Spread / Average Target

+106.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KORRO BIO, INC.	+31.30%	584M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research